Europe Launches Probe into Pharma Deals

The European Commission yesterday launched a probe into the pharmaceutical industry's settlements with generics firms, questioning whether such deals breech the EU's competition laws and restrict consumers' access to medicines. Increasingly, drugs companies, such as GlaxoSmithKline (GSK) and AstraZeneca (AZN) have struck deals with generic competitors in an effort to preserve revenues on high earning treatments. The move follows a report on the industry last year that promised action on delays in getting drugs to market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.